Immune Checkpoint Inhibitors in Bladder Cancer, NSCLC, and Malignant Melanoma | Access & Reimbursement | US | 2019
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-priced immune checkpoint inhibitors gain label expansions for additional indications, and approvals as part of combinatorial regimens, the high cost associated with these agents will continue to present significant challenges for payers. Developing a clear understanding of prescribing patterns and the reimbursement landscape for immune checkpoint inhibitors is critical to maximize commercial success.
QUESTIONS ANSWERED
- What role do immune checkpoint inhibitors play in the treatment of oncology indications such as NSCLC, malignant melanoma, and bladder cancer?
- What are the key driving forces and constraints that influence MCO reimbursement decisions for immune checkpoint inhibitors?
- Do access and reimbursement challenges for these agents differ by indication?
- How do payers prioritize diminishing budgets and control prescribing of immune checkpoints accordingly?
- What are medical oncologists’ views on select emerging immune checkpoint inhibitors in late-phase development?
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED: Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, Bavencio.
CONTENT HIGHLIGHTS:
- Actionable recommendations to optimize market access.
- Market access successes and stumbles.
- Reimbursement and contracting.
- Access and prescribing.
- Special topics.
- Opportunities and challenges for emerging therapies.
